BioSpecifics Technology Corp. published a paper on Tuesday detailing the efficacy of its collagenase clostridium histolyicum (CCH) vaccine prototype for the treatment of uterine fibroids, finding a decreased fibroid stiffness.
The article, titled “Loss of Stiffness in Collagen-Rich Uterine Fibroids after Digestion with Purified Collagenase Clostridium Histolyticum,” was published in the American Journal of Obstetrics & Gynecology. It showed that highly purified CCH could decrease stiffness in uterine fibroid ex-vivo, and might also cause a reduction in fibroid size.
Uterine fibroids are becoming increasingly common in the U.S. Seventy to 80 percent of women are expected to experience a uterine fibroid by the age of 50.
BioSpecifics expects to organize a CCH trial later this year. Read more here: